Micafungin - Astellas Pharma

Drug Profile

Micafungin - Astellas Pharma

Alternative Names: FK 463; Funguard; Micafungin sodium; Micamin; Mycamine

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antifungals; Echinocandins; Lipoproteins
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidaemia; Candidiasis

Most Recent Events

  • 07 Sep 2015 Launched for Aspergillosis in USA (IV) before September 2015
  • 01 Dec 2014 Astellas Pharma terminates a phase III trial in Candidiasis (In neonates, In children) in USA, Brazil, Bulgaria, Canada, Colombia, Greece, Hungary, Israel, Philippines, Romania, Turkey and Ukraine (NCT00815516)
  • 01 Sep 2013 Astellas Pharma is enrolling patients in a phase IV trial (CFDA commitment) in Candidiasis in China (NCT01982071)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top